Effect of Nicotinamide Mononucleotide (NMN) Supplementation on Metabolic and Muscle Function in Prediabetes

reportActive / Technical Report | Accesssion Number: AD1115264 | Open PDF

Abstract:

The overall goal of the study is to expand our pilot clinical study and further evaluate the translation of our preclinical findings of NMN supplementation on metabolic health in rodents to clinical therapy in people. To this end, we will conduct a randomized placebo-controlled trial in men and women with prediabetes to assess the effect of NMN supplementation on key metabolic, mitochondrial and inflammation outcomes in collaboration with VA St. Louis Health Care System (VASTLHCS). We coordinated the implementation of the research protocol with Washington University (WU) and VASTLHCS; finalized the study protocol and informed consent form to be used at WU and VASTLHCS; obtained WU IRB approval (December 5, 2019), VASTLHCS IRB (March 17, 2020), and VASTLHCS RDC (April 24, 2020); had obtain obtained a WOC appointment at VASTLHCS for three WU study team members; and obtained DoD HRPO approval (September 19, 2020). The study is registered at Clinicaltrials.gov. We are actively recruiting study participants.

Author(s):
Klein, Samuel ; Yoshino, Mihoko
Author Organization(s):
WASHINGTON UNIV ST LOUIS MO
Funding Organization(s):
Publication Date:
2020 Oct 01
Pagination:
0

Security Markings

RECORD

Collection: TRECMS
Subject Terms
Communities of Interest:
No COI(s) Identified
Descriptor(s):
department of veterans affairs, liver diseases, department of defense, public health, biomedical research, health, health care, management personnel, covid-19, health services, medical personnel, body weight, organizational structure, civilian personnel, dysfunction, glucose metabolism disorders, gut microbiome
Keyword(s):
Prediabetes, insulin sensitivity, Nicotinamide mononucleotide, NMN supplementation
Subject Categories:
Biological and Medical Sciences
Update Date:
2020 Dec 08